ZYOMYX is a biotechnology startup that focuses on developing expertly engineered, affordable solutions for challenging point-of-care needs in diverse global landscapes. The company has a strong capability in addressing complex and unconventional challenges, particularly in the health care and pharmaceutical industries.
One of ZYOMYX's key strengths lies in their ability to develop highly user-friendly, instrument-free point-of-care tests while meeting strict cost targets. They excel in addressing stringent product demands by leveraging advanced cartridge engineering and reagent stability. Currently, the company's priority is the development of a sophisticated yet easy-to-use and affordable CD4 T-cell point-of-care test, tailored to meet the critical needs of low and middle-income countries.
Founded in 1998, ZYOMYX received a significant $7.50 million grant investment on 26th March 2014. The investor details for this particular investment round are not specified.
